Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von C K Zigler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Quality of Life, Scleroderma, Localized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Background
The Localized Scleroderma Quality of Life Instrument (LoSQI) is a disease‐specific patient‐reported outcome (PRO) measure designed for children and adolescents with localized scleroderma (LS; morphea). This tool was developed using rigorous PRO methods and previously cognitively tested in a sample of paediatric patients with LS.
Objective
The purpose of this study was to evaluate the psychometric properties of the LoSQI in a clinical setting.
Methods
Cross‐sectional data from four specialized clinics in the US and Canada were included in the analysis. Evaluation included reliability of scores, internal structure of the survey, evidence of convergent and divergent validity, and test–retest reliability.
Results
One hundred and ten patients with LS (age: 8–20 years) completed the LoSQI. Both exploratory and confirmatory factor analysis supported the use of two sub‐scores: Pain and Physical Functioning, and Body Image and Social Support. Correlations with other PRO measures were consistent with pre‐specified hypotheses.
Limitations
This study did not evaluate longitudinal validity or responsiveness of scores.
Conclusion
Results from a representative sample of children and adolescents with LS continue to support the validity of the LoSQI when used in a clinical setting. Future work to evaluate the responsiveness is ongoing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
- Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Department of Dermatology, UT Southwestern Medical Center, Dallas, Texas, USA.
- School of Education, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack Meridian School of Medicine, Hackensack, New Jersey, USA.
ORCID-Profile: C K Zigler
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Zigler, C. K., Lin, L., Ardalan, K., Jacobe, H., Lane, S., Li, S. C., Luca, N. J. C., Prajapati, V. H., Schollaert, K., Teske, N., & Torok, K. (2023). Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19059
Vancouver
Zigler CK, Lin L, Ardalan K, Jacobe H, Lane S, Li SC, et al. Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19059
BibTeX
@article{Zigler2023,
author = {Zigler, C K and Lin, L and Ardalan, K and Jacobe, H and Lane, S and Li, S C and Luca, N J C and Prajapati, V H and Schollaert, K and Teske, N and Torok, K},
title = {Cross‐sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument ( LoSQI ): A disease‐specific patient‐reported outcome measure},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19059}
}
EUVIMED